Michael Gelband’s Candel Therapeutics CADL Stock Holding History

Michael Gelband’s Portfolio CADL Stock Details CADL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-227,468	Closed	-$1.11M	–	1610
2026 Q1	$1.11M	Buy	+227,468	New	+$1.24M	0.01%	967

Other funds holding CADL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Michael Gelband's CADL Position: Q2 2026 in Review

Michael Gelband sold out of Candel Therapeutics (CADL) in Q2 2026, closing a stake of 227,468 shares — an estimated $1.11M sold.

Michael Gelband first reported a position in CADL in Q1 2026 and held it in 1 quarter. The position peaked at $1.11M in Q1 2026. 137 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

Michael Gelband reported no remaining Candel Therapeutics position as of Q2 2026 after selling out during the quarter.
Michael Gelband sold 227,468 Candel Therapeutics shares in Q2 2026, an estimated $1.11M.
Michael Gelband first reported a position in Candel Therapeutics in Q1 2026 and held it in 1 quarter.
Michael Gelband's Candel Therapeutics position peaked at $1.11M in Q1 2026.
137 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.